ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.

Quote:

Search for Ticker

Free Membership

Search:

MAPP: Map Pharmaceuticals Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

MAP PHARMACEUTICALS INC (NASD)
MAPP	9.17	-0.06	(-0.65%)	Vol. 98,274	16:00 ET

Located in Mountain View, California, MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including the two most advanced product candidates: a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine.

General Information

MAP PHARMACEUT

2400 Bayshore Parkway Suite 200 Mountain View, CA 94043 Phone: 650 386-3100 Fax: 650 386-3101 Web: www.mappharma.com Email: hr@mappharma.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/08/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	9.23
52 Week High	13.85
52 Week Low	1.57
Beta	2.51
20 Day Moving Average	87,799.25
Target Price Consensus	13.2

% Price Change
4 Week	4.77
12 Week	2.44
YTD	32.24

% Price Change Relative to S&P 500
4 Week	0.76
12 Week	-7.53
YTD	3.75

Share Information
Shares Outstanding (millions)	24.41
Market Capitalization (millions)	225.29
Short Ratio	7.59
Last Split Date	N/A

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.40
Current Year EPS Consensus Estimate	-0.25
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	03/08/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.00
30 Days Ago	1.00
60 Days Ago	1.00
90 Days Ago	1.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	180.00%
vs. Previous Quarter	433.33%

Sales Growth
vs. Previous Year	-%
vs. Previous Quarter:	308.02%

Price Ratios
Price/Book	4.21
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-96.29
06/30/09	-432.44
03/31/09	-262.18

ROA
09/30/09	-25.13
06/30/09	-86.84
03/31/09	-97.70

Current Ratio
09/30/09	3.80
06/30/09	1.66
03/31/09	1.82

Quick Ratio
09/30/09	3.80
06/30/09	1.66
03/31/09	1.82

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-33.91
06/30/09	-353.65
03/31/09	-915.69

Pre-Tax Margin
09/30/09	-33.91
06/30/09	-353.65
03/31/09	-915.69

Book Value
09/30/09	2.19
06/30/09	0.06
03/31/09	0.22

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	0.17
06/30/09	8.44
03/31/09	2.80

Debt to Capital
09/30/09	14.59
06/30/09	89.41
03/31/09	73.65


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research